{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:44Z","timestamp":1772165804814,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801360"],"award-info":[{"award-number":["81801360"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese academy of medical sciences","award":["2019PT310020"],"award-info":[{"award-number":["2019PT310020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A number of studies have shown that genetic factor plays an important role in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two hundred thirty-three patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4\u2009weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR\u2009=\u20090.624, 95% CI 0.450\u20130.864,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), and a significant result was found in the dominant model (OR\u2009=\u20090.546; 95% CI, 0.371\u20130.804,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR\u2009=\u20090.205, 95% CI 0.128\u20130.328; OR\u2009=\u20090.249, 95% CI 0.155\u20130.401, both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-020-02790-y","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T08:02:53Z","timestamp":1595923373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder"],"prefix":"10.1186","volume":"20","author":[{"given":"Zhili","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjiao","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-2801","authenticated-orcid":false,"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2790_CR1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archpsyc.55.9.801","volume":"55","author":"RC Kessler","year":"1998","unstructured":"Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry. 1998;55:801\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"2790_CR2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/archpsyc.63.4.415","volume":"63","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63:415\u201324.","journal-title":"Arch Gen Psychiatry"},{"key":"2790_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jmg.2010.086876","volume":"48","author":"J Schumacher","year":"2011","unstructured":"Schumacher J, Kristensen AS, Wendland JR, N\u00f6then MM, Mors O, FJ MM. The genetics of panic disorder. J Med Genet. 2011;48:361\u20138.","journal-title":"J Med Genet"},{"key":"2790_CR4","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1176\/appi.ajp.158.10.1568","volume":"158","author":"JM Hettema","year":"2001","unstructured":"Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158:1568\u201378.","journal-title":"Am J Psychiatry"},{"key":"2790_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.npp.1300880","volume":"31","author":"E Maron","year":"2006","unstructured":"Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology. 2006;31:1\u201311.","journal-title":"Neuropsychopharmacology."},{"key":"2790_CR6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neubiorev.2016.10.013","volume":"76","author":"FG Graeff","year":"2017","unstructured":"Graeff FG. Translational approach to the pathophysiology of panic disorder: focus on serotonin and endogenous opioids. Neurosci Biobehav Rev. 2017;76:48\u201355.","journal-title":"Neurosci Biobehav Rev"},{"key":"2790_CR7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1586\/ern.10.110","volume":"10","author":"MD Mochcovitch","year":"2010","unstructured":"Mochcovitch MD, Nardi AE. Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. Expert Rev Neurother. 2010;10:1285\u201393.","journal-title":"Expert Rev Neurother"},{"key":"2790_CR8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S1461145704004985","volume":"8","author":"E Maron","year":"2005","unstructured":"Maron E, Lang A, Tasa G, Liivlaid L, T\u00f5ru I, Must A, et al. Associations between serotonin-related gene polymorphisms and panic disorder. Int J Neuropsychopharmacol. 2005;8:261\u20136.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2790_CR9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mp.2008.79","volume":"15","author":"LJ Strug","year":"2010","unstructured":"Strug LJ, Suresh R, Fyer AJ, Talati A, Adams PB, Li W, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). Mol Psychiatry. 2010;15:166\u201376.","journal-title":"Mol Psychiatry"},{"key":"2790_CR10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4306\/pi.2017.14.1.86","volume":"14","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Ishiguro S, Aoki A, Ueda M, Hayashi Y, Akiyama K, et al. Genetic polymorphism of 1019C\/G (rs6295) promoter of serotonin 1A receptor and catechol-O-methyltransferase in panic disorder. Psychiatry Investig. 2017;14:86\u201392.","journal-title":"Psychiatry Investig"},{"key":"2790_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4306\/pi.2010.7.2.141","volume":"7","author":"WS Choi","year":"2010","unstructured":"Choi WS, Lee BH, Yang JC, Kim YK. Association study between 5-HT1A receptor gene C(\u22121019)G polymorphism and panic disorder in a Korean population. Psychiatry Investig. 2010;7:141\u20136.","journal-title":"Psychiatry Investig"},{"key":"2790_CR12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.janxdis.2008.03.006","volume":"22","author":"HK Yoon","year":"2008","unstructured":"Yoon HK, Yang JC, Lee HJ, Kim YK. The association between serotonin-related gene polymorphisms and panic disorder. J Anxiety Disord. 2008;22:1529\u201334.","journal-title":"J Anxiety Disord"},{"key":"2790_CR13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neulet.2004.04.010","volume":"363","author":"C Rothe","year":"2004","unstructured":"Rothe C, Koszycki D, Bradwejn J, King N, De Luca V, Shaikh S, et al. Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neurosci Lett. 2004;363:276\u20139.","journal-title":"Neurosci Lett"},{"key":"2790_CR14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pnpbp.2011.10.010","volume":"36","author":"G Karacetin","year":"2012","unstructured":"Karacetin G, Bayoglu B, Cengiz M, Demira T, Kocabasoglu N, Uysal O, et al. Serotonin-2A receptor and catechol-O-methyltransferase polymorphisms in panic disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;36:5\u201310.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2790_CR15","doi-asserted-by":"crossref","unstructured":"Rothe C, Koszycki D, Bradwejn J, King N, De Luca, V, Tharmalingam S, et al. Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. Neuropsychopharmacology. 2006; 31:2237\u20132242.","DOI":"10.1038\/sj.npp.1301048"},{"key":"2790_CR16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.psychres.2009.11.022","volume":"178","author":"K Annerbrink","year":"2010","unstructured":"Annerbrink K, Westberg L, Olsson M, Olsson M, Allgulander S, Andersch S, et al. Association between the catechol-O-methyltransferase Val158Met polymorphism and panic disorder: a replication. Psychiatry Res. 2010;178:196\u20138.","journal-title":"Psychiatry Res"},{"key":"2790_CR17","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/jama.296.13.1609","volume":"296","author":"H Kim","year":"2006","unstructured":"Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA. 2006;296:1609\u201318.","journal-title":"JAMA."},{"key":"2790_CR18","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2147\/NDT.S93562","volume":"12","author":"ZQ Dong","year":"2016","unstructured":"Dong ZQ, Li XR, He L, He G, Yu T, Sun XL. 5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients. Neuropsychiatr Dis Treat. 2016;12:1623\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2790_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00213-012-2813-y","volume":"225","author":"W Myung","year":"2013","unstructured":"Myung W, Lim SW, Kim S, Kim H, Chung JW, Seo MY, et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology. 2013;225:283\u201390.","journal-title":"Psychopharmacology"},{"key":"2790_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.6061\/clinics\/2012(04)06","volume":"67","author":"FM Corregiari","year":"2012","unstructured":"Corregiari FM, Bernik M, Cordeiro Q, Vallada H. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder. Clinics (Sao Paulo). 2012;67:335\u201340.","journal-title":"Clinics (Sao Paulo)"},{"key":"2790_CR21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajmg.b.30783","volume":"150B","author":"M Kato","year":"2009","unstructured":"Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:115\u201323.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2790_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jad.2010.06.002","volume":"127","author":"E Gudayol-Ferr\u00e9","year":"2010","unstructured":"Gudayol-Ferr\u00e9 E, Herrera-Guzm\u00e1n I, Camarena B, Cort\u00e9s-Penagos C, Herrera-Abarca JE, Mart\u00ednez-Medina P, et al. The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. J Affect Disord. 2010;127:343\u201351.","journal-title":"J Affect Disord"},{"key":"2790_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/0971-5916.166596","volume":"142","author":"A Basu","year":"2015","unstructured":"Basu A, Chadda RK, Sood M, Kaur H, Kukreti R. Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: a preliminary study. Indian J Med Res. 2015;142:40\u20135.","journal-title":"Indian J Med Res"},{"key":"2790_CR24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","volume":"45","author":"T Niitsu","year":"2013","unstructured":"Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;45:183\u201394.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2790_CR25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2005.11.008","volume":"90","author":"B Arias","year":"2006","unstructured":"Arias B, Serretti A, Lorenzi C, Gast\u00f3 C, Catal\u00e1n R, Fa\u00f1an\u00e1s L. Analysis of COMT gene (Val 158 met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord. 2006;90:251\u20136.","journal-title":"J Affect Disord"},{"key":"2790_CR26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hup.2267","volume":"27","author":"E Gudayol-Ferr\u00e9","year":"2012","unstructured":"Gudayol-Ferr\u00e9 E, Herrera-Guzm\u00e1n I, Camarena B, Cort\u00e9s-Penagos C, Herrera-Abarca JE, Mart\u00ednez-Medina P, et al. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic\/dopaminergic gene polymorphisms. Hum Psychopharmacol. 2012;27:577\u201386.","journal-title":"Hum Psychopharmacol"},{"key":"2790_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/JCP.0000000000000454","volume":"36","author":"S Nonen","year":"2016","unstructured":"Nonen S, Kato M, Takekita Y, Wakeno M, Sakai S, Serretti A, et al. Polymorphism of rs3813034 in serotonin transporter gene SLC6A4 is associated with the selective serotonin and serotonin-norepinephrine reuptake inhibitor response in depressive disorder: sequencing analysis of SLC6A4. J Clin Psychopharmacol. 2016;36:27\u201331.","journal-title":"J Clin Psychopharmacol"},{"key":"2790_CR28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/08039488.2015.1012554","volume":"69","author":"K Andre","year":"2015","unstructured":"Andre K, Kampman O, Illi A, Viikki M, Set\u00e4l\u00e4-Soikkeli E, Mononen N, et al. SERT and NET polymorphisms, temperament and antidepressant response. Nord J Psychiatry. 2015;69:531\u20138.","journal-title":"Nord J Psychiatry"},{"key":"2790_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpsychires.2014.11.017","volume":"61","author":"YW Yeh","year":"2015","unstructured":"Yeh YW, Chen CJ, Jang FL, Kuo SC, Chen CY, Liang CS, et al. SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population. J Psychiatr Res. 2015;61:33\u20139.","journal-title":"J Psychiatr Res"},{"key":"2790_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNF.0000000000000315","volume":"42","author":"B Camarena","year":"2019","unstructured":"Camarena B, \u00c1lvarez-Icaza D, Hern\u00e1ndez S, Aguilar A, M\u00fcnch L, Mart\u00ednez C, et al. Association study between serotonin transporter gene and Fluoxetine response in Mexican patients with major depressive disorder. Clin Neuropharmacol. 2019;42:9\u201313.","journal-title":"Clin Neuropharmacol"},{"key":"2790_CR31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4088\/JCP.v68n0512","volume":"68","author":"D Denys","year":"2007","unstructured":"Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68:747\u201353.","journal-title":"J Clin Psychiatry"},{"key":"2790_CR32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.tpj.6500289","volume":"5","author":"A Szegedi","year":"2005","unstructured":"Szegedi A, Rujescu D, Tadic A, M\u00fcller MJ, Kohnen R, Stassen HH, et al. The catechol-O-methyltransferase Val108\/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5:49\u201353.","journal-title":"Pharmacogenomics J"},{"key":"2790_CR33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.yic.0000171518.25963.63","volume":"20","author":"K Kamijima","year":"2005","unstructured":"Kamijima K, Kuboki T, Kumano H, Burt T, Cohen G, Arano I, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol. 2005;20:265\u201373.","journal-title":"Int Clin Psychopharmacol"},{"key":"2790_CR34","volume-title":"Structured clinical interview for DSM-IV Axis I disorders (SCID-I) (clinical version)","author":"MB First","year":"1997","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV Axis I disorders (SCID-I) (clinical version). Washington DC: American Psy-chiatric Press Inc; 1997."},{"key":"2790_CR35","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ajp.154.11.1571","volume":"154","author":"MK Shear","year":"1997","unstructured":"Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154:1571\u20135.","journal-title":"Am J Psychiatry"},{"key":"2790_CR36","first-page":"285","volume":"45","author":"HF Xiong","year":"2012","unstructured":"Xiong HF, Li ZJ, Han HY, Xu ZY, Guo ZH, Yao SM, et al. Panic disorder severity scale-chinese version: reliability and validity. Chin J Psychiatry. 2012;45:285\u20138.","journal-title":"Chin J Psychiatry"},{"key":"2790_CR37","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/da.20532","volume":"26","author":"TA Furukawa","year":"2009","unstructured":"Furukawa TA, Katherine Shear M, Barlow DH, Gorman JM, Woods SW, Money R, et al. Evidence-based guidelines for interpretation of the panic disorder severity scale. Depress Anxiety. 2009;26:922\u20139.","journal-title":"Depress Anxiety"},{"key":"2790_CR38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YPG.0000000000000171","volume":"27","author":"AJ Forstner","year":"2017","unstructured":"Forstner AJ, Rambau S, Friedrich N, Ludwig KU, B\u00f6hmer AC, Mangold E, et al. Further evidence for genetic variation at the serotonin transporter gene SLC6A4 contributing toward anxiety. Psychiatr Genet. 2017;27:96\u2013102.","journal-title":"Psychiatr Genet"},{"key":"2790_CR39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.pnpbp.2005.03.012","volume":"29","author":"KP Lesch","year":"2005","unstructured":"Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29:1062\u201373.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"2790_CR40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnbeh.2015.00047","volume":"9","author":"C Bodden","year":"2015","unstructured":"Bodden C, Richter SH, Schreiber RS, Kloke V, Ger\u00df J, Palme R, et al. Benefits of adversity?! How life history affects the behavioral profile of mice varying in serotonin transporter genotype. Front Behav Neurosci. 2015;9:47.","journal-title":"Front Behav Neurosci"},{"key":"2790_CR41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fnbeh.2016.00097","volume":"10","author":"N Meyer","year":"2016","unstructured":"Meyer N, Richter SH, Schreiber RS, Kloke V, Kaiser S, Lesch KP, et al. The unexpected effects of beneficial and adverse social experiences during adolescence on anxiety and aggression and their modulation by genotype. Front Behav Neurosci. 2016;10:97.","journal-title":"Front Behav Neurosci"},{"key":"2790_CR42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.euroneuro.2010.08.005","volume":"21","author":"SJ Line","year":"2011","unstructured":"Line SJ, Barkus C, Coyle C, Jennings KA, Deacon RM, Lesch KP, et al. Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur Neuropsychopharmacol. 2011;21:108\u201316.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2790_CR43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1888-9891(09)70712-8","volume":"2","author":"PA Saiz","year":"2009","unstructured":"Saiz PA, Mart\u00ednez-Barrondo S, Garc\u00eda-Portilla MP, Corcoran P, Morales B, Bascaran MT, et al. Role of serotonergic polymorphisms in the clinical severity of the panic disorder. Rev Psiquiatr Salud Ment. 2009;2:35\u201341.","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"2790_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1744-9081-3-41","volume":"3","author":"C Blaya","year":"2007","unstructured":"Blaya C, Salum GA, Lima MS, Leistner-Segal S, Manfro GG. Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and panic disorder: a systematic review and meta-analysis. Behav Brain Funct. 2007;3:41.","journal-title":"Behav Brain Funct"},{"key":"2790_CR45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2009.10.015","volume":"67","author":"S Gyawali","year":"2010","unstructured":"Gyawali S, Subaran R, Weissman MM, Hershkowitz D, McKenna MC, Talati A, et al. Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. Biol Psychiatry. 2010;67:331\u20138.","journal-title":"Biol Psychiatry"},{"key":"2790_CR46","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/mp.2015.138","volume":"21","author":"AS Howe","year":"2016","unstructured":"Howe AS, Buttensch\u00f8n HN, Bani-Fatemi A, Maron E, Otowa T, Erhardt A, et al. Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways. Mol Psychiatry. 2016;21:665\u201379.","journal-title":"Mol Psychiatry"},{"key":"2790_CR47","doi-asserted-by":"crossref","unstructured":"Maron E, Nikopensius T, K\u00f5ks S, Altm\u00e4e S, Heinaste E, Vabrit K, et al. Association study of 90 candidategene polymorphisms in panic disorder. Psychiatr Genet. 2005;15:17\u201324.","DOI":"10.1097\/00041444-200503000-00004"},{"key":"2790_CR48","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1471-4159.1996.66062621.x","volume":"66","author":"A Heils","year":"1996","unstructured":"Heils A, Teufel A, Petri S, St\u00f6ber G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621\u20134.","journal-title":"J Neurochem"},{"key":"2790_CR49","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","volume":"274","author":"KP Lesch","year":"1996","unstructured":"Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527\u201331.","journal-title":"Science."},{"key":"2790_CR50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.1071829","volume":"297","author":"AR Hariri","year":"2002","unstructured":"Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400\u20133.","journal-title":"Science."},{"key":"2790_CR51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1086\/503850","volume":"78","author":"XZ Hu","year":"2006","unstructured":"Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive\u2013compulsive disorder. Am J Hum Genet. 2006;78:815\u201326.","journal-title":"Am J Hum Genet"},{"key":"2790_CR52","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.euroneuro.2014.05.007","volume":"24","author":"I Knuts","year":"2014","unstructured":"Knuts I, Esquivel G, Kenis G, Overbeek T, Leibold N, Goossens L, et al. Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia. Eur Neuropsychopharmacol. 2014;24:1222\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2790_CR53","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1177\/0269881109106899","volume":"24","author":"W Umene-Nakano","year":"2010","unstructured":"Umene-Nakano W, Yoshimura R, Ueda N, Suzuki A, Ikenouchi-Sugita A, Hori H, et al. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol. 2010;24:1764\u201371.","journal-title":"J Psychopharmacol"},{"key":"2790_CR54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2009.09.007","volume":"123","author":"OO Yevtushenko","year":"2010","unstructured":"Yevtushenko OO, Oros MM, Reynolds GP. Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord. 2010;123:308\u201311.","journal-title":"J Affect Disord"},{"key":"2790_CR55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/gte.2007.0089","volume":"12","author":"O Dogan","year":"2008","unstructured":"Dogan O, Yuksel N, Ergun MA, Yilmaz A, Ilhan MN, Karslioglu HE, et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test. 2008;12:225\u201331.","journal-title":"Genet Test"},{"key":"2790_CR56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FPC.0000000000000290","volume":"27","author":"Q He","year":"2017","unstructured":"He Q, Yuan Z, Liu Y, Zhang J, Yan H, Shen L, et al. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenet Genomics. 2017;27:279\u201384.","journal-title":"Pharmacogenet Genomics"},{"key":"2790_CR57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neulet.2016.12.071","volume":"669","author":"AJ Lisoway","year":"2018","unstructured":"Lisoway AJ, Zai CC, Tiwari AK, Kennedy JL. DNA methylation and clinical response to antidepressant medication in major depressive disorder: a review and recommendations. Neurosci Lett. 2018;669:14\u201323.","journal-title":"Neurosci Lett"},{"key":"2790_CR58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euroneuro.2011.10.003","volume":"22","author":"S Porcelli","year":"2012","unstructured":"Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22:239\u201358.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2790_CR59","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00228-011-1073-9","volume":"67","author":"S Ishiguro","year":"2011","unstructured":"Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, et al. Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol. 2011;67:1213\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"2790_CR60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jpsychires.2004.01.001","volume":"38","author":"JM Woo","year":"2004","unstructured":"Woo JM, Yoon KS, Choi YH, Oh KS, Lee YS, Yu BH. The association between panic disorder and the L\/L genotype of catechol-O-methyltransferase. J Psychiatr Res. 2004;38:365\u201370.","journal-title":"J Psychiatr Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02790-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T19:23:03Z","timestamp":1627413783000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02790-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2790"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02790-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-16543\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16543\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-16543\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"27 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Sichuan Provincial People\u2019s Hospital ethics committee, reference number: (2016) Ethics Review (29). All individuals provided written informed consent prior to the initiation of study procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}